Cancer and systemic sclerosis: Novel insights into pathogenesis and clinical implications

Current Opinion in Rheumatology

Volumn 23, Issue 6, 2011, Pages 530-535

  Shah, Ami A ^a   Rosen, Antony ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Autoantibodies; Cancer; Paraneoplastic; Systemic sclerosis

Indexed keywords

AUTOANTIBODY; AUTOANTIGEN; DNA DIRECTED RNA POLYMERASE III;

ANTIBODY RESPONSE; ANTIGEN EXPRESSION; AUTOIMMUNITY; CANCER DIAGNOSIS; CANCER RISK; CANCER TISSUE; CROSS REACTION; DISEASE ASSOCIATION; HUMAN; MYOSITIS; PARANEOPLASTIC SYNDROME; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SCLERODERMA; SYSTEMIC SCLEROSIS; TARGET ORGAN; TISSUE INJURY; TISSUE REGENERATION;

AUTOANTIGENS; AUTOIMMUNITY; ESOTROPIA; HUMANS; MODELS, IMMUNOLOGICAL; NEOPLASMS; PARANEOPLASTIC SYNDROMES; RISK FACTORS; RNA POLYMERASE III; SCLERODERMA, SYSTEMIC;

EID: 82955248068     PISSN: 10408711     EISSN: 15316963     Source Type: Journal    
DOI: 10.1097/BOR.0b013e32834a5081     Document Type: Review

References (58)

1. Olesen AB, Svaerke C, Farkas DK, Sorensen HT. Systemic sclerosis and the risk of cancer: a nationwide population-based cohort study. Br J Dermatol 2010; 163:800-806.
2. Abu-Shakra M, Guillemin F, Lee P. Cancer in systemic sclerosis. Arthritis Rheum 1993; 36:460-464. (Pubitemid 23104032)
3. Derk CT, Rasheed M, Artlett CM, Jimenez SA. A cohort study of cancer incidence in systemic sclerosis. J Rheumatol 2006; 33:1113-1116. (Pubitemid 43825461)
4. Hill CL, Nguyen AM, Roder D, Roberts-Thomson P. Risk of cancer in patients with scleroderma: a population based cohort study. Ann Rheum Dis 2003; 62:728-731. (Pubitemid 36886406)
5. Rosenthal AK, McLaughlin JK, Gridley G, Nyren O. Incidence of cancer among patients with systemic sclerosis. Cancer 1995; 76:910-914.
6. Rosenthal AK, McLaughlin JK, Linet MS, Persson I. Scleroderma and malignancy: an epidemiological study. Ann Rheum Dis 1993; 52:531-533. (Pubitemid 23227219)
7. Peters-Golden M, Wise RA, Hochberg M, et al. Incidence of lung cancer in systemic sclerosis. J Rheumatol 1985; 12:1136-1139. (Pubitemid 16166459)
8. Siau K, Laversuch CJ, Creamer P, O'Rourke KP. Malignancy in scleroderma patients from south west England: a population-based cohort study. Rheumatol Int 2011; 31:641-645.
9. Levine SM. Cancer and myositis: new insights into an old association. Curr Opin Rheumatol 2006; 18:620-624. (Pubitemid 44607417)
10. Roumm AD, Medsger TA Jr. Cancer and systemic sclerosis: an epidemiologic study. Arthritis Rheum 1985; 28:1336-1340. (Pubitemid 16156143)
11. Hasegawa M, Sato S, Sakai H, et al. Systemic sclerosis revealing T-cell lymphoma. Dermatology 1999; 198:75-78. (Pubitemid 29086341)
12. Juarez M, Marshall R, Denton C, Evely R. Paraneoplastic scleroderma secondary to hairy cell leukaemia successfully treated with cladribine. Rheumatology (Oxford) 2008; 47:1734-1735.
13. Forbes AM, Woodrow JC, Verbov JL, Graham RM. Carcinoma of breast and scleroderma: four further cases and a literature review. Br J Rheumatol 1989; 28:65-69. (Pubitemid 19107405)
14. Launay D, Le Berre R, Hatron PY, et al. Association between systemic sclerosis and breast cancer: eight new cases and review of the literature. Clin Rheumatol 2004; 23:516-522. (Pubitemid 39562258)
15. Scope A, Sadetzki S, Sidi Y, et al. Breast cancer and scleroderma. Skinmed 2006; 5:18-24.
16. Bachleitner-Hofmann T, Machold K, Knobler R, et al. Marked and sustained improvement of systemic sclerosis following polychemotherapy for coexistent multiple myeloma. Clin Exp Rheumatol 2002; 20:85-88. (Pubitemid 34213741)
17. Cohen IS, Mosher MB, O'Keefe EJ, et al. Cutaneous toxicity of bleomycin therapy. Arch Dermatol 1973; 107:553-555.
18. Finch WR, Rodnan GP, Buckingham RB, et al. Bleomycin-induced scleroderma. J Rheumatol 1980; 7:651-659. (Pubitemid 11160461)
19. Berger CC, Bokemeyer C, Schneider M, et al. Secondary Raynaud's phenomenon and other late vascular complications following chemotherapy for testicular cancer. Eur J Cancer 1995; 31A:2229-2238. (Pubitemid 26050564)
20. Bessis D, Guillot B, Legouffe E, Guilhou JJ. Gemcitabine-associated scleroderma- like changes of the lower extremities. J Am Acad Dermatol 2004; 51 (2 Suppl):S73-S76.
21. Clowse ME, Wigley FM. Digital necrosis related to carboplatin and gemcitabine therapy in systemic sclerosis. J Rheumatol 2003; 30:1341-1343. (Pubitemid 36666363)
22. Varga J, Haustein UF, Creech RH, et al. Exaggerated radiation-induced fibrosis in patients with systemic sclerosis. JAMA 1991; 265:3292-3295.
23. Colver GB, Rodger A, Mortimer PS, et al. Postirradiation morphoea. Br J Dermatol 1989; 120:831-835.
24. Shah AA, Rosen A, Hummers L, et al. Close temporal relationship between onset of cancer and scleroderma in patients with RNA polymerase I/III antibodies. Arthritis Rheum 2010; 62:2787-2795.
25. Duncan SC, Winkelmann RK. Cancer and scleroderma. Arch Dermatol 1979; 115:950-955. (Pubitemid 10156552)
26. Winkelmann RK, Flach DB, Unni KK. Lung cancer and scleroderma. Arch Dermatol Res 1988; 280(Suppl):S15-S18.
27. Szekanecz E, Szamosi S, Gergely L, et al. Incidence of lymphoma in systemic sclerosis: a retrospective analysis of 218 Hungarian patients with systemic sclerosis. Clin Rheumatol 2008; 27:1163-1166.
28. Comer M, Harvey AR. Remission of scleroderma during chemotherapy for lymphoma. Ann Rheum Dis 1992; 51:998-1000.
29. Williams RC Jr. Dermatomyositis and malignancy: a review of the literature. Ann Intern Med 1959; 50:1174-1181.
30. Barnes BE, Mawr B. Dermatomyositis and malignancy: a review of the literature. Ann Intern Med 1976; 84:68-76.
31. Hill CL, Zhang Y, Sigurgeirsson B, et al. Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study. Lancet 2001; 357:96-100. (Pubitemid 32094911)
32. Zantos D, Zhang Y, Felson D. The overall and temporal association of cancer with polymyositis and dermatomyositis. J Rheumatol 1994; 21:1855-1859. (Pubitemid 24312647)
33. Buchbinder R, Forbes A, Hall S, et al. Incidence of malignant disease in biopsy-proven inflammatory myopathy: a population-based cohort study. Ann Intern Med 2001; 134:1087-1095.
34. Sigurgeirsson B, Lindelof B, Edhag O, Allander E. Risk of cancer in patients with dermatomyositis or polymyositis: a population-based study. N Engl JMed 1992; 326:363-367.
35. Sunnenberg TD, Kitchens CS. Dermatomyositis associated with malignant melanoma: parallel occurrence, remission, and relapse of the two processes in a patient. Cancer 1983; 51:2157-2158. (Pubitemid 13092475)
36. Verducci MA, Malkasian GD Jr, Friedman SJ, Winkelmann RK. Gynecologic carcinoma associated with dermatomyositis-polymyositis. Obstet Gynecol 1984; 64:695-698. (Pubitemid 15205478)
37. Casciola-Rosen L, Nagaraju K, Plotz P, et al. Enhanced autoantigen expression in regenerating muscle cells in idiopathic inflammatory myopathy. J Exp Med 2005; 201:591-601. (Pubitemid 40289549)
38. Mammen AL, Casciola-Rosen LA, Hall JC, et al. Expression of the dermatomyositis autoantigen mi-2 in regenerating muscle. Arthritis Rheum 2009; 60:3784-3793.
39. Darnell JC, Albert ML, Darnell RB. Cdr2, a target antigen of naturally occurring human tumor immunity, is widely expressed in gynecological tumors. Cancer Res 2000; 60:2136-2139. (Pubitemid 30225174)
40. Buckanovich RJ, Posner JB, Darnell RB. Nova, the paraneoplastic Ri antigen, is homologous to an RNA-binding protein and is specifically expressed in the developing motor system. Neuron 1993; 11:657-672. (Pubitemid 23321775)
41. Buckanovich RJ, Yang YY, Darnell RB. The onconeural antigen nova-1 is a neuron-specific RNA-binding protein, the activity of which is inhibited by paraneoplastic antibodies. J Neurosci 1996; 16:1114-1122. (Pubitemid 26140868)
42. Furneaux HM, Rosenblum MK, Dalmau J, et al. Selective expression of Purkinje-cell antigens in tumor tissue from patients with paraneoplastic cerebellar degeneration. N Engl J Med 1990; 322:1844-1851. (Pubitemid 20200410)
43. Darnell RB, Posner JB. Paraneoplastic syndromes involving the nervous system. N Engl J Med 2003; 349:1543-1554. (Pubitemid 37255041)
44. Albert ML, Darnell JC, Bender A, et al. Tumor-specific killer cells in paraneoplastic cerebellar degeneration. Nat Med 1998; 4:1321-1324. (Pubitemid 28512116)
45. Dalmau J, Furneaux HM, Rosenblum MK, et al. Detection of the antihu antibody in specific regions of the nervous system and tumor from patients with paraneoplastic encephalomyelitis/sensory neuronopathy. Neurology 1991; 41:1757-1764.
46. Dalmau J, Furneaux HM, Gralla RJ, et al. Detection of the antihu antibody in the serum of patients with small cell lung cancer: a quantitative western blot analysis. Ann Neurol 1990; 27:544-552. (Pubitemid 20149976)
47. Darnell RB, DeAngelis LM. Regression of small-cell lung carcinoma in patients with paraneoplastic neuronal antibodies. Lancet 1993; 341:21-22. (Pubitemid 23007597)
48. Bystryn JC, Rigel D, Friedman RJ, Kopf A. Prognostic significance of hypopigmentation in malignant melanoma. Arch Dermatol 1987; 123: 1053-1055. (Pubitemid 17134848)
49. Nordlund JJ, Kirkwood JM, Forget BM, et al. Vitiligo in patients with metastatic melanoma: a good prognostic sign. J Am Acad Dermatol 1983; 9:689-696. (Pubitemid 14230566)
50. Uchi H, Stan R, Turk MJ, et al. Unraveling the complex relationship between cancer immunity and autoimmunity: lessons from melanoma and vitiligo. Adv Immunol 2006; 90:215-241. (Pubitemid 43765798)
51. Quaglino P, Marenco F, Osella-Abate S, et al. Vitiligo is an independent favourable prognostic factor in stage III and IV metastatic melanoma patients: results from a single-institution hospital-based observational cohort study. Ann Oncol 2010; 21:409-414.
52. Boasberg PD, Hoon DS, Piro LD, et al. Enhanced survival associated with vitiligo expression during maintenance biotherapy for metastatic melanoma. J Invest Dermatol 2006; 126:2658-2663. (Pubitemid 44764050)
53. Jacobs JF, Aarntzen EH, Sibelt LA, et al. Vaccine-specific local T cell reactivity in immunotherapy-associated vitiligo in melanoma patients. Cancer Immunol Immunother 2009; 58:145-151.
54. Fishman P, Merimski O, Baharav E, Shoenfeld Y. Autoantibodies to tyrosinase: the bridge between melanoma and vitiligo. Cancer 1997; 79:1461-1464. (Pubitemid 27154773)
55. Airo P, Ceribelli A, Cavazzana I, et al. Malignancies in Italian patients with systemic sclerosis positive for anti-RNA polymerase III antibodies. J Rheumatol 2011; 38:1329-1334.
56. Soussi T. p53 antibodies in the sera of patients with various types of cancer: a review. Cancer Res 2000; 60:1777-1788. (Pubitemid 30207629)
57. Engelhorn ME, Guevara-Patino JA, Noffz G, et al. Autoimmunity and tumor immunity induced by immune responses to mutations in self. Nat Med 2006; 12:198-206. (Pubitemid 43214746)
58. Kuwana M, Fujii T, Mimori T, Kaburaki J. Enhancement of anti-DNA topoisomerase I autoantibody response after lung cancer in patients with systemic sclerosis: a report of two cases. Arthritis Rheum 1996; 39:686-691. (Pubitemid 26119641)